Results 81 to 90 of about 30,445,587 (352)

Dlgh1 coordinates actin polymerization, synaptic T cell receptor and lipid raft aggregation, and effector function in T cells. [PDF]

, 2005
Lipid raft membrane compartmentalization and membrane-associated guanylate kinase (MAGUK) family molecular scaffolds function in establishing cell polarity and organizing signal transducers within epithelial cell junctions and neuronal synapses. Here, we
Miceli, M Carrie, Patel, Viresh, Round, June L, Schoenberger, Stephen P, Tomassian, Tamar, Zhang, Min   +5 more
core  

CD155 on HIV-infected cells is not modulated by HIV-1 Vpu and Nef but synergizes with NKG2D ligands to trigger NK cell lysis of autologous primary HIV-infected cells [PDF]

, 2017
Activation of primary CD4(+) T cells induces the CD155, but not the CD112 ligands for the natural killer (NK) cell activation receptor (aNKR) CD226 [DNAX accessory molecule-1 (DNAM-1)].
Barker, Edward, Cogswell, Andrew, Davis, Zacharay B, Plannelles, Vincente, Sowriajan, Bharatwaj, Ward, Jeffrey P   +5 more
core   +2 more sources

Zinc finger protein Zfp335 is required for the formation of the naïve T cell compartment

eLife, 2014
The generation of naïve T lymphocytes is critical for immune function yet the mechanisms governing their maturation remain incompletely understood. We have identified a mouse mutant, bloto, that harbors a hypomorphic mutation in the zinc finger protein ...
Brenda Y Han, Shuang Wu, Chuan-Sheng Foo, Robert M Horton, Craig N Jenne, Susan R Watson, Belinda Whittle, Chris C Goodnow, Jason G Cyster   +8 more
doaj   +1 more source

Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. [PDF]

, 1993
Cognate interactions between antigen-presenting B and T cells play crucial roles in immunologic responses. T cells that have been activated via the crosslinking of CD3 are able to induce B cell proliferation and immunoglobulin secretion in a major ...
Kipps, TJ, Ranheim, EA
core  

Preferences of Pediatric Patients and Their Caregivers for Chemotherapy‐Induced Nausea and Vomiting Control Endpoints: A Mixed Methods Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Although not always achieved, complete chemotherapy‐induced nausea and vomiting (CINV) control is the conventional goal of CINV prophylaxis. In this two‐center, mixed‐methods study, we sought to understand the preferences of adolescent patients and family caregivers for CINV control endpoints.
Haley Newman, Tadi Hondonga, Alison Berry, Caitlin Elgarten, Jason Freedman, Katelyn Oranges, Sara McDonough, Caroline Diorio, L. Lee Dupuis   +8 more
wiley   +1 more source

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Nature Reviews Clinical Oncology, 2019
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven — and impressive — therapeutic activity in patients with certain subtypes of B cell leukaemia or lymphoma, with promising efficacy also demonstrated in patients with ...
S. Rafiq, Christopher S. Hackett, R. Brentjens   +2 more
semanticscholar   +1 more source

Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. [PDF]

, 2018
Chimeric antigen receptor (CAR) T cell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of
Avanzi, Mauro P, Brentjens, Renier J, Cheung, Kenneth, Daniyan, Anthony F, Li, Xinghuo, Park, Hyebin, Purdon, Terence J, Spitzer, Matthew H, van Leeuwen, Dayenne G, Wijewarnasuriya, Dinali P, Yeku, Oladapo   +10 more
core   +1 more source

Intravitreal GD2‐Specific Chimeric Antigen Receptor T‐Cell Therapy for Refractory Retinoblastoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Effective treatments for advanced, treatment‐resistant retinoblastoma (RB) remain limited. GD2‐specific chimeric antigen receptor (CAR) T cells show potent antitumor activity with minimal toxicity but have not previously been evaluated in RB.
Subongkoch Subhadhirasakul, Jatuporn Sujjitjoon, Pa‐thai Yenchitsomanus, Kridtin Jarutatsanangkoon, Ng Wei Loon, Kleebsabai Sanpakit, Jassada Buaboonnam, Chayamon Takpradit, Pornpimon Yuti, Nunghathai Sawasdee, Piriya Luangwattananun, Siripakorn Sangkitporn, Arnan Limmahachai, La‐ongsri Atchaneeyasakul   +13 more
wiley   +1 more source

Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy

eLife, 2014
Clinically effective antigen-based immunotherapy must silence antigen-experienced effector T cells (Teff) driving ongoing immune pathology. Using CD4+ autoimmune Teff cells, we demonstrate that peptide immunotherapy (PIT) is strictly dependent upon ...
Rhoanne C McPherson, Joanne E Konkel, Catriona T Prendergast, John P Thomson, Raffaele Ottaviano, Melanie D Leech, Oliver Kay, Stephanie E J Zandee, Claire H Sweenie, David C Wraith, Richard R Meehan, Amanda J Drake, Stephen M Anderton   +12 more
doaj   +1 more source

Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment

OncoImmunology, 2020
Although anti-programmed death-1 (PD-1) treatment has shown remarkable anti-tumor efficacy, immune-related adverse events (irAEs) develop with heterogeneous clinical manifestations.
Kyung Hwan Kim, Joon Young Hur, Jinhyun Cho, Bo Mi Ku, Jiae Koh, June Young Koh, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn, Eui-Cheol Shin   +11 more
doaj   +1 more source